ENXTPA:SANPharmaceuticals
Sanofi Immunology Advances Test Long Term Case Beyond Recent Share Weakness
Sanofi has entered a global licensing agreement with Kali Therapeutics for KT501, a tri specific T cell engager for autoimmune diseases currently in clinical trials for rheumatoid arthritis.
Dupixent has received regulatory approval in Japan for moderate to severe bullous pemphigoid, a rare and serious dermatologic condition with limited treatment options.
These developments expand Sanofi's immunology and rare disease franchises, highlighting progress in first in class and best in class...